Short Stocks: Bets build against Cell Therapeutics, RIM eases

Mon Apr 12, 2010 7:22pm EDT

 NEW YORK, April 12 (Reuters) - Short interest on the New
York Stock Exchange fell at the end of March, while bearish
bets on the Nasdaq rose in the same period, the exchanges said
on Monday. For story please see [ID:nN12213519].
 The following list shows stocks that saw an increase or
decrease in interest from short sellers, who bet that a certain
stock's price will fall, and key recent news events for those
stocks. The data reflect short trades with a settlement date of
March 31.
 Short interest rose 15.4 percent to 103 million shares
 A U.S. advisory panel said in late March that Cell
Therapeutics had not collected enough data to win clearance for
an experimental lymphoma drug, sending its shares tumbling.
 Cell Therapeutics has since said it plans to request a
meeting with the Food and Drug Administration.
 Short interest fell 36.4 percent to 13.5 million shares
 Starbucks declared its first dividend in late March,
ushering in a broader-based strategy aimed at more sustainable,
stable prosperity. [ID:nN24149620]
 The company also said it was ready to again expand its U.S.
store base and restart international expansion.
 Short interest fell 15.6 percent to 15.2 million shares
 Bearish bets in the BlackBerry-maker fell ahead of its
quarterly earnings, which were released at the end of March.
 The company reported that profit and sales rose in the
fourth quarter, but the results lagged expectations and
underscored worries that the dominance of its smartphone is
waning. [ID:nN26209697]
 Short interest rose 8.5 percent to 48.1 million shares
 Schlumberger said in March the company will have difficulty
meeting Wall Street's profit forecasts this year, because
rising natural gas drilling in North America will not lead to
"satisfactory returns" this year. [ID:nN22228671]
 The company also announced in March it is buying French
drilling analysis firm Geoservices for just over $1 billion.
 (Reporting by Leah Schnurr; Editing by Steve Orlofsky)